Precigen/$PGEN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Precigen
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
- Ticker
- $PGEN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 160
- Headquarters
- Germantown, United States
- Website
- precigen.com
Precigen Metrics
BasicAdvanced
$1.7B
69.60
$0.07
0.98
-
Price and volume
Market cap
$1.7B
Beta
0.98
52-week high
$8.98
52-week low
$3.04
Average daily volume
6.8M
Financial strength
Current ratio
5.579
Quick ratio
4.635
Long term debt to equity
1.163
Total debt to equity
1.177
Interest coverage (TTM)
2.85%
Profitability
EBITDA (TTM)
38.08
Gross margin (TTM)
74.51%
Net profit margin (TTM)
15.55%
Operating margin (TTM)
21.43%
Effective tax rate (TTM)
0.81%
Revenue per employee (TTM)
$980,000
Management effectiveness
Return on assets (TTM)
10.97%
Return on equity (TTM)
38.84%
Valuation
Price to earnings (TTM)
69.602
Price to revenue (TTM)
10.705
Price to book
20.2
Price to tangible book (TTM)
25.51
Price to free cash flow (TTM)
-22.607
Free cash flow yield (TTM)
-4.42%
Free cash flow per share (TTM)
-0.209
Growth
Revenue change (TTM)
2,387.61%
Earnings per share change (TTM)
-104.73%
3-year revenue growth (CAGR)
185.28%
10-year revenue growth (CAGR)
-1.71%
3-year earnings per share growth (CAGR)
-42.98%
10-year earnings per share growth (CAGR)
-26.59%
What the Analysts think about Precigen
Analyst ratings (Buy, Hold, Sell) for Precigen stock.
Analyst projections of the future price of Precigen stock.
Bulls say / Bears say
PAPZIMEOS sales rose 37% quarter on quarter to $72.9 million in Q3, helping Precigen report $35.8 million net income and positive operating cash flow a quarter ahead of guidance. That is evidence the launch is gaining commercial traction and beginning to fund the business. (Precigen)
PAPZIMEOS has a promising efficacy and durability profile: the pivotal study recorded a 51% complete response rate, and follow-up reported durable complete responses for up to five years. Simple administration and these results may help it retain physician and patient interest as the market grows. (Precigen, The Motley Fool)
The FDA’s platform technology designation for AdenoVerse could let Precigen reuse manufacturing and preclinical knowledge to streamline development of future candidates. PRGN-2009 is already in Phase 2 studies for HPV-associated cancers, although its clinical value remains to be proven. (Precigen, Precigen)
A rival RRP treatment has received conditional FDA approval, creating a new competitive threat to PAPZIMEOS. A competing option could limit future growth if physicians or patients favour its treatment approach, even though Precigen argues its own efficacy and established access give it an edge. (The Motley Fool, MarketBeat)
Precigen remains heavily reliant on one product: PAPZIMEOS generated $72.9 million of the company’s $74.1 million in Q3 revenue. A slowdown or setback for that drug would therefore have an outsized effect on sales. (Precigen)
Cash conversion still merits attention: Precigen reported $96.5 million in trade receivables against $51 million in cash and investments at quarter end, while it has $100 million of debt outstanding. Its 10-Q says customer payment terms are generally 127 days, so delays in collecting sales could put pressure on liquidity. (Precigen, SEC)
Data summarised monthly by Lightyear AI. Last updated on 5 Nov 2026.
Precigen Financial Performance
Revenues and expenses
Precigen Earnings Performance
Company profitability
Upcoming events
No upcoming events
Precigen News
AllArticlesVideos
Funds containing Precigen
Fund name | Fund size | $PGEN weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.3B | 0.10% |
iShares Nasdaq US Biotechnology$BTEC | $1.3B | 0.10% |
SPDR Russell 2000 US Small Cap€R2US | $5B | 0.03% |
SPDR Russell 2000 US Small Cap£R2SC | $5B | 0.03% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $2.7B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.